Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial

Nitz, Ulrike; Gluz, Oleg; Christgen, Matthias; Kates, Ronald; Clemens, Michael; Malter, Wolfram; Nuding, Benno; Aktas, Bahriye; Küemmel, Sherko; Reimer, Toralf; Stefek, Andrea; Lorenz-Salehi, Fatemeh; Krabisch, Petra; Just, Marianne; Augustin, Doris; Liedtke, Cornelia; Chao, Calvin; Shak, Steven; Wuerstlein, Rachel; Kreipe, Hans; Harbeck, Nadia

doi:10.1007/s10549-017-4358-6

Public

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial

Published in Breast Cancer Research and Treatment • Jun 29, 2017

Authors:

Ulrike Nitz

Oleg Gluz

Matthias Christgen

Abstract

BACKGROUND: (RS) to define a genomically low-risk subset of clinically high-risk pN0-1 early breast cancer (EBC) patients for treatment with adjuvant endocrine therapy (ET) alone. Here, we report five-year data evaluating the prognostic value of RS, Ki-67, and other traditional clinicopathological p...

Subject

Medicine

Internal medicine

Breast cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!